Recurrent Malignant Glioma Industry Market Trends, Size And Growth Analysis 2017 To 2022

Overview

Recurrent malignant glioma is defined as recurrence of tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back, or leg caused by tumors in the neck area of the spinal cord and weakness in the limbs or upper body. Treatment includes chemotherapy and radiation therapy.

 Click here for sample report @ http://www.wiseguyreports.com/sample-request/2740076-recurrent-malignant-glioma-pipeline-review-h2-2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Recurrent Malignant Glioma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Recurrent Malignant Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Recurrent Malignant Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 4 and 3 molecules, respectively.

 Major Scope of the report:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma (Oncology). 
- The pipeline guide reviews pipeline therapeutics for Recurrent Malignant Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. 
- The pipeline guide reviews key companies involved in Recurrent Malignant Glioma (Oncology) therapeutics and enlists all their major and minor projects. 

Table of Contents 

List of Tables 
List of Figures 
Introduction 
Global Markets Direct Report Coverage 
Recurrent Malignant Glioma - Overview 
Recurrent Malignant Glioma - Therapeutics Development 
Pipeline Overview 
Pipeline by Companies 
Pipeline by Universities/Institutes 
Products under Development by Companies 
Products under Development by Universities/Institutes 
Recurrent Malignant Glioma - Therapeutics Assessment 
Assessment by Target 
Assessment by Mechanism of Action 
Assessment by Route of Administration 
Assessment by Molecule Type 
Recurrent Malignant Glioma - Companies Involved in Therapeutics Development 
AbbVie Inc 
Boehringer Ingelheim GmbH 
GtreeBNT Co Ltd 
Recurrent Malignant Glioma - Drug Profiles 
afatinib dimaleate - Drug Profile 
Product Description  

 .Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2740076-recurrent-malignant-glioma-pipeline-review-h2-2017

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

WISEGUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Pune - 411028
Maharashtra, India

This release was published on openPR.